Main Line Fertility is the only fertility center in the greater Philadelphia area that offers its patients non-invasive preimplantation genetic testing (ni-PGT-A) of embryos. Non-invasive preimplantation testing can be used to screen embryos for aneupoidy, which is too few or too many chromosomes. Aneuploidy can lead to IVF failure or miscarriage and occurs randomly in embryos during development. The ni-PGT-A report from the genetics lab will indicate which embryos have the normal number of chromosomes. Additionally, the genetics report allows patients to know the sex of their embryos if they wish. In a subsequent frozen embryo transfer cycle, a normal embryo can be thawed and transferred to the uterus to optimize your chances of a successful pregnancy and a healthy baby.

HOW NON-INVASIVE PGT IS PERFORMED

Unlike traditional biopsy for PGT, non invasive preimplantation genetic testing involves sampling the DNA from the culture media surrounding the embryo, and it does not involve removing cells from the embryo itself.

PATIENTS WHO MAY CHOOSE NON-INVASIVE PGT INCLUDE
      • Patients over the age of 34
      • Patients who have experienced repeated IVF failure
      • Patients with a history of miscarriage
      • Patients who do not want to incur cryostorage fees of chromosomally abnormal embryos
      • Patients who wish to reduce their risk of miscarriage and genetic abnormalities
      • Patients interested in sex selection for family balancing

“We chose to do non-invasive preimplantation genetic testing on our embryos because we wanted to have the best chance for a successful and healthy pregnancy.”

– Ashley & Mike

INVESTMENT

The cost of preimplantation genetic testing begins at $2,500 and includes the day 3 embryo preparation, DNA sampling of the blastocyst’s culture medium and packaging of the culture samples. The final cost of PGT is dependent on how many embryos are tested.

FREQUENTLY ASKED QUESTIONS

Not all embryos created will develop to the blastocyst stage. Only good quality blastocysts on day 5, day 6 or day 7 of culture can be biopsied.

Non-invasive PGT-A reduces the chance of having a chromosomally abnormal pregnancy but does not replace prenatal testing.

Your Main Line Fertility physician will partner with you to decide if non-invasive PGT-A is beneficial based on your medical history and personal preferences.

Some insurances will cover non-invasive PGT-A. Patients should contact their insurance carriers to determine coverage prior to their IVF cycle.

Non-invasive PGT-A is able to identify the sex of your embryo(s), and if you wish to know the sex we can share that information with you. Patients can specify the gender they prefer for embryo transfer. We are not able to change or guarantee a particular sex.

While non-invasive PGT can greatly reduce your chance of experiencing a miscarriage or having a child with a genetic disorder, it cannot guarantee that they will not occur.

For more information about non-invasive preimplantation testing, please contact our patient care advocate.